Xinbang Pharmaceutical released its performance for the first half of the year, with a net profit attributable to the parent company of 107 million yuan, a decrease of 6.69%

According to the Zhitong Finance APP, Xinbang Pharmaceutical (002390.SZ) released its semi-annual report for 2025, reporting an operating income of 2.845 billion yuan, a year-on-year decrease of 6.62%. The net profit attributable to shareholders of the listed company was 107 million yuan, a year-on-year decrease of 6.69%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 107 million yuan, a year-on-year decrease of 7.16%. The basic earnings per share were 0.0565 yuan